Day: November 21, 2019

SUNNYVALE, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) — Fortinet® (NASDAQ: FTNT), a global leader in broad, integrated and automated cybersecurity solutions, today announced that it has been chosen by Ooredoo Kuwait, a part of Ooredoo Group – a leading international communications company operating across the Middle East, North Africa and Southeast Asia – to deliver the region’s first secure SD-WAN managed service. Fortinet Secure SD-WAN will allow Ooredoo’s existing and new enterprise customers to achieve accelerated connectivity, transport mode independence, and increased application performance while benefiting from tightly knit SD-WAN and advanced security features. Ooredoo Kuwait itself is deploying Fortinet’s Secure SD-WAN across its retail branches and will serve as a reference for customers wishing to follow suit.“Ooredoo Kuwait’s...

BOSTON and JERUSALEM, Nov. 21, 2019 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX) today announced that it has established a U.S. Headquarters in the Boston area and has hired Jonathan Lieber as its U.S.-based CFO. Mr. Lieber will be responsible for all investor relations, finance and administrative functions, and will lead the Company’s future financing efforts to support the company’s growth initiatives.“We are pleased to have an accomplished executive of Jon’s caliber join Entera Bio.  We welcome his long experience at emerging life science companies and his strong investor and banking relationships,” stated Adam Gridley, CEO of Entera.  “As the company builds its presence with its stakeholders, the addition of Jon as our U.S.-based CFO will be critical to support our future growth, and our lead clinical programs and in our...

–  41 percent objective response rate (ORR) as assessed by the investigator in 42 patients who were primary refractory to anti-PD-1/L1 therapy –             – Median duration of response (DOR) was not reached as assessed by investigator at 12 months of study follow-up for the primary refractory subgroup –SAN CARLOS, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced results of a subgroup analysis of Cohort 2 of the Phase 2 lifileucel metastatic melanoma study C-144-01 in patients who were primary refractory to prior anti-PD-1/L1 therapy. An abstract with details of the analysis was accepted as a late-breaking poster at the 16th International Congress of the Society for...

ALACHUA, Fla., Nov. 21, 2019 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at the Piper Jaffray 31st Annual Healthcare Conference in New York City. The presentation is scheduled for Thursday, December 5, 2019 at 8:10 a.m. ET.The presentation will be webcast live and accessible through the Investors page at www.axogeninc.com. For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on www.axogeninc.com.About AxogenAxogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve...

VANCOUVER, British Columbia, Nov. 21, 2019 (GLOBE NEWSWIRE) — Calibre Mining Corp. (TSX: CXB) (the “Company” or “Calibre”) announces the temporary suspension of blasting activities at its Jabali underground mine at La Libertad. The suspension is related to surface instability issues caused by localised artisanal mining. The Company is supporting the government and community to mitigate the risks facing approximately 25 households in the community of Santo Domingo, proximal to the Jabali underground mine. The Company expects to resume blasting and full mining activities at Jabali underground prior to year-end. Mining at the Jabali open-pit remains unaffected and the Company continues to process ore at its La Libertad mill. Despite the temporary suspension of blasting at Jabali underground, the Company has reaffirmed its fourth quarter...

Company Launches with $19 Million in Funding and Rights to IV Meloxicam, Along with Other Clinical-Stage Pipeline AssetsTrading of “BXRX” Begins Tomorrow on NASDAQMALVERN, Pa., Nov. 21, 2019 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (NASDAQ:BXRX) today announced its launch as an independent, publicly traded pharmaceutical company focused on advancing non-opioid analgesics and other products for the hospital and other acute care settings.  Beginning tomorrow, November 22, 2019, Baudax will trade on the NASDAQ Capital Market under the ticker symbol “BXRX.” When-issued trading under the symbol “BXRXV” continues until market close today.“Baudax Bio will pursue the development of therapeutics, specifically focusing on innovative products for acute care settings where there is an urgent need and the potential for the greatest impact for patients,”...

AUSTIN, Texas, Nov. 21, 2019 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, today announced the pricing of its underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $8.00 per share and 250 shares of its newly designated Series A convertible preferred stock at a public offering price of $8,000 per share. Each share of Series A convertible preferred stock will be convertible into 1,000 shares of common stock at the holder’s option, subject to beneficial ownership limitations. All of the shares of common stock and Series A convertible...

LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that it received Orphan Drug designation (ODD) from the Food and Drug Administration (FDA) for QR-1123.QR-1123 is a first-in-class investigational antisense oligonucleotide designed to address the underlying cause of vision loss associated with autosomal dominant retinitis pigmentosa (adRP) due to the P23H mutation in the rhodopsin (RHO) gene.ODD provides a special status for investigational drugs being developed for rare diseases. The ODD program offers development program tax benefits and a waiver of the NDA application user fee, as well as market exclusivity for up to seven years...

WAYNE, Pa., Nov. 21, 2019 (GLOBE NEWSWIRE) — Liam Kelly, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 31st Annual Piper Jaffray Healthcare Conference at The Lotte New York Palace Hotel, in New York City, on Thursday, December 5, 2019 at 9:00 a.m. (ET). A live audio webcast of the conference presentation, along with the accompanying slide presentation, will be available on the investor section of the Teleflex website at www.teleflex.com.About Teleflex IncorporatedTeleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional...